Suggesting a testing strategy for possible endocrine effects of drug metabolites

Regulatory Toxicology and Pharmacology

Volumn 62, Issue 3, 2012, Pages 441-448

  Jacobsen, N W ^a   Brooks, B W ^b   Halling Sorensen B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b BAYLOR UNIVERSITY   (United States)

Author keywords

Aromatase; CYP19; In vitro; Metabolism; Selective serotonin reuptake inhibitors; SSRI

Indexed keywords

AROMATASE; CARBAMIC ACID SERTRALINE; DRUG METABOLITE; HYDROXY KETONE SERTRALINE; KETONE SERTRALINE; N DESMETHYL SERTRALINE; N HYDROXY SERTRALINE; SERTRALINE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE SYNTHESIS; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; REACTION TIME;

AROMATASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCRINE SYSTEM; HUMANS; MICROSOMES, LIVER; SERTRALINE; TOXICITY TESTS;

EID: 84857676182     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2012.02.003     Document Type: Article

References (30)

1. Amsterdam J.D., Garcia-Espana F., Goodman D., Hooper M., Hornig-Rohan M. Breast enlargement during chronic antidepressant therapy. J. Affect. Disord. 1997, 46(2):151-156.
2. Ankley G.T., Brooks B.W., Huggett D.B., Sumpter J.P. Repeating history: pharmaceuticals in the environment. Environ. Sci. Technol. 2007, 41(24):8211-8217.
3. Bell S., Shipman M., Bystritsky A., Haifley T. Fluoxetine treatment and testosterone levels. Ann. Clin. Psychiatry 2006, 18(1):19-22.
4. Berenbaum M. The expected effect of a combination of agents: the general solution. J. Theor. Biol. 1985, 114(3):412-431.
5. Boxall A.B.A., Sinclair C.J., Fenner K., Kolpin D., Maud S.J. When synthetic chemicals degrade in the environment. Environ. Sci. Technol. 2004, 38(19):368A-375A.
6. Coecke S., Ahr H., Blaauboer B.J., Bremer S., et al. Metabolism: a bottleneck in in vitro toxicological test development - The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 2006, 34:49-84.
7. DeVane C.L., Liston H.L., Markowitz J.S. Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 2002, 41(15):1247-1266.
8. Escher B.I., Fenner K. Recent advances in the environmental risk assessment of transformation products. Environ. Sci. Technol. 2011, 45:3835-3847.
9. Foran C.M., Weston J., Slattery M., Brooks B.W., Huggett D.B. Reproductive assessment of Japanese medaka (Oryzias latipes) following a four-week fluoxetine (SSRI) exposure. Arch. Environ. Contam. Toxicol. 2004, 46(4):511-517.
10. Ganesan S., Sahu R., Walker L.A., Tekwani B.L. Cytochrome P-450-dependent toxicity of dapsone in human erythrocytes. J. Appl. Toxicol. 2010, 30(3):271-275.
11. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. Antidepressant-induced sexual dysfunction. Ann. Pharmacother. 2002, 36(10):1577-1589.
12. Halling-Sorensen B., Sengelov G., Ingerslev F., Jensen L.B. Reduced antimicrobial potencies of oxytetracycline, tylosin, sulfadiazin, streptomycin, ciprofloxacin, and olaquindox due to environmental processes. Arch. Environ. Contam. Toxicol. 2003, 44(1):7-16.
13. Hardman J.G., Limbird L.E. Goodman & Gilman's: The Pharmacological Basis of Therapeutics 2001, McGraw-Hill, New York, (p. 2148). tenth ed.
14. Hiemke C., Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol. Ther. 2000, 85(1):11-28.
15. Hotchkiss A.K., Rider C.V., Blystone C.R., Wilson V.S., Hartig P.C., Ankley G.T., Foster P.M., Gray C.L., Gray L.E. Fifteen years after " Wingspread" - Environmental endocrine disrupters and human and wildlife health: Where we are today and where we need to go. Toxicol. Sci. 2008, 105(2):235-259.
16. Jacobsen, N., Yassin, S., Nellemann, C., and Halling-Sorensen, B., submitted for publication. Effect of selective serotonin reuptake inhibitors in aromatase supersomes and H295R cells. Mol. Cell. Toxicol.
17. Lister A., Regan C., Van Zwol J., Van Der Kraak G. Inhibition of egg production in zebrafish by fluoxetine and municipal effluents: A mechanistic evaluation. Aquat. Toxicol. 2009, 95(4):320-329.
18. Mennigen J.A., Lado W.E., Zamora J.M., Duarte-Guterman P., Langlois V.S., Metcalfe C.D., Chang J.P., Moon T.W., Trudeau V.L. Waterborne fluoxetine disrupts the reproductive axis in sexually mature male goldfish, Carassius auratus. Aquat. Toxicol. 2010, 100(4):354-364.
19. Nalecz-Jawecki G. Evaluation of the in vitro biotransformation of fluoxetine with HPLC, mass spectrometry and ecotoxicological tests. Chemosphere 2007, 70(1):29-35.
20. Nalecz-Jawecki G. In vitro biotransformation of amitriptyline and imipramine with rat hepatic S9 fraction: evaluation of the toxicity with Spirotox and Thamnotoxkit F (TM) tests. Arch. Environ. Contam. Toxicol. 2008, 54(2):266-273.
21. Nalecz-Jawecki G., Wojcik T., Sawicki J. Evaluation of in vitro biotransformation of propranolol with HPLC, MS/MS, and two bioassays. Environ. Toxicol. 2008, 23(1):52-58.
22. Neuwoehner J., Fenner K., Escher B.I. Physiological modes of action of fluoxetine and its human metabolites in algae. Environ. Sci. Technol. 2009, 43(17):6830-6837.
23. Obach R.S., Cox L.M., Tremaine L.M. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab. Dispos. 2005, 33(2):262-270.
24. Otto M., Hansen S.H., Dalgaard L., Dubois J., Badolo L. Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Cell Biol. Toxicol. 2007.
25. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997, 283(3):1305-1322.
26. Rudberg I., Hermann M., Refsum H., Molden E. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur. J. Clin. Pharmacol. 2008, 64(12):1181-1188.
27. Safarinejad M. Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. J. Clin. Psychopharmacol. 2008, 28(4):418-423.
28. Saha S., New L.S., Ho H.K., Chui W.K., Chan E.C.Y. Direct toxicity effects of sulfo-conjugated troglitazone on human hepatocytes. Toxicol. Lett. 2010, 195(2-3):135-141.
29. Sanderson J.T., Letcher R.J., Heneweer M., Giesy J.P., van den Berg M. Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ. Health Perspect. 2001, 109(10):1027-1031.
30. Steiner M., Lamont J., Steinberg S., Stewart D., Reid R., Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstet. Gynecol. 1997, 90(4):590-595.